⚠ LIVE — European Consumer Safety Watch 💊 Medicinsk kanal: 18 Under de senaste 7 dagarna 🍎 kanal.mat.label: 180 Under de senaste 7 dagarna 🧸 Produkter i kanalen: 48 Under de senaste 7 dagarna 🟢 Övervakning: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Senaste hämtning: för 5 timmar sedan ⚠ LIVE — European Consumer Safety Watch 💊 Medicinsk kanal: 18 Under de senaste 7 dagarna 🍎 kanal.mat.label: 180 Under de senaste 7 dagarna 🧸 Produkter i kanalen: 48 Under de senaste 7 dagarna 🟢 Övervakning: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Senaste hämtning: för 5 timmar sedan
🛡️ EUSW
🇸🇪
💊

Eliquis

apixaban
Arthroplastik; venös tromboembolism
✅ Auktoriserad
Inga aktiva aviseringar
Denna medicin har inga pågående brister, säkerhetsbrev eller återkallelser.

Vad det används till

Treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age. AdultsPrevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).Paediatric population Treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age. AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age. 

⚠️ Patientsäkerhet

No

⚠️ Vi sammanställer officiella meddelanden. Vi lämnar ingen medicinsk rådgivning. För medicinska eller juridiska beslut, rådfråga den ansvariga myndigheten och en kvalificerad yrkesutövare.